Table 3 Multivariate analysis of factors affecting RFS of patients with breast cancers of different molecular subtypes
Clinico-pathological feature | Luminal A | Luminal B | TNBC with basal-like p value, (HR;CI) | HER2-enriched |
|---|---|---|---|---|
p value (HR;CI) | p value (HR;CI) | p value (HR; CI) | ||
Age (≤ 35, 36–60,> 60 years) | – | – | – | 0.014 |
Lymph node stage | – | – | – | 0.025* |
Stage 2 | 0.031 (3.805; 1.130–12.811) | |||
Stage 3 | 0.005 (6.487;1.740–24.180) | |||
Claudin-low | 0.004 | – | – | – |
5.506 (1.710–17.734) | ||||
Overall KIBRA-low | – | – | – | – |